

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	3	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	4	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	5	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	6	JUN 25	CA/CAPLUS and USPAT databases updated with IPC reclassification data
NEWS	7	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	8	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	9	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	10	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS	11	JUL 28	CA/CAPLUS patent coverage enhanced
NEWS	12	JUL 28	EPFULL enhanced with additional legal status information from the epline Register
NEWS	13	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	14	JUL 28	STN Viewer performance improved
NEWS	15	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	16	AUG 13	CA/CAPLUS enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	17	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	18	AUG 15	CAPLUS currency for Korean patents enhanced
NEWS	19	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS	20	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS	21	SEP 25	CA/CAPLUS current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS	22	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and Korean patents enhanced
NEWS	23	SEP 29	IFICLS enhanced with new super search field
NEWS	24	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS	25	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS	26	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS	27	OCT 07	Multiple databases enhanced for more flexible patent number searching

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:14:41 ON 21 OCT 2008

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:14:46 ON 21 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 OCT 2008 HIGHEST RN 1063823-70-0
DICTIONARY FILE UPDATES: 20 OCT 2008 HIGHEST RN 1063823-70-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10540371.str



chain nodes :

11 19

ring nodes :

1 2 3 4 5 6 7 8 9 12 13 14 15 16

chain bonds :

4-11 5-12 9-19

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 12-13 12-16 13-14 14-15 15-16

exact/norm bonds :

2-7 3-9 4-11 5-12 7-8 8-9 9-19 12-13 12-16 13-14 14-15 15-16

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 12 :

G1:C,O,S,N

G2:H,Ak

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:CLASS
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 19:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,O,S,N

G2 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 15:15:07 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 842 TO ITERATE

100.0% PROCESSED 842 ITERATIONS

334 ANSWERS

SEARCH TIME: 00.00.01

L2 334 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.57

FILE 'CAPLUS' ENTERED AT 15:15:11 ON 21 OCT 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Oct 2008 VOL 149 ISS 17
FILE LAST UPDATED: 20 Oct 2008 (20081020/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l2 full

L3 4 L2

=> d ibib abs hitstr tot

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:1128140 CAPLUS

DOCUMENT NUMBER: 149:378733

TITLE: Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors and their preparation, pharmaceutical composition and use in the treatment of diseases

INVENTOR(S): Rudra, Sonali; Gupta, Nidhi; Baregama, Lalit Kumar; Agarwal, Ritu; Khairnar, Vinayak Vasanttrao; Ramaiah, Mandadapu Raghu; Palle, Venkata P.; Balachandran, Sarala; Kondaskar, Atul; Salla, Manohar; Ray, Abhijit; Dastidar, Sunanda G.; Vijaykrishnan, Lalitha

PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India

SOURCE: PCT Int. Appl., 188pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008111010	A1	20080918	WO 2008-IB50943	20080314
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.:

IN 2007-DE550

A 20070314

GI




AB The invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4 /PDE type 7 inhibitors. Comps. disclosed herein having the structure of formula I: can be useful in the treatment, prevention, inhibition or suppression of CNS diseases, for example, multiple sclerosis; various pathol. conditions such as diseases affecting the immune system, including AIDS, rejection of transplant, auto-immune disorders such as T-cell related diseases, for example, rheumatoid arthritis; inflammatory diseases such as respiratory inflammation diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) and other inflammatory diseases including but not limited to psoriasis, shock, atopic dermatitis, eosinophilic granuloma, allergic conjunctivitis, osteoarthritis; gastrointestinal inflammation diseases such as Crohn's disease, colitis, pancreatitis as well as different types of cancers including leukemia; especially in humans. Processes for the preparation of disclosed comps. of formula I, pharmaceutical comps. containing the disclosed comps. and their use as PDE type 4, PDE type 7 and dual PDE type 4 /PDE type 7 inhibitors are provided. Comps. of formula I wherein R1 and R2 are independently H, (hetero)aryl, CHO, acyl, SH and derivs., SOH and derivs., SO2H and derivs., etc.; R3 is H, alkyl, alkenyl, alkynyl, cycloalkyl, (hetero)arylalkyl, etc.; ring M is (un)substituted 3- to 7-membered ring; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention comps. were evaluated for their PDE-4 and PDE-7 inhibitory activity. From the assay, it was determined that the tested comps. exhibited IC50 values in the range of 3 nM to 10 μ M.

IT 1056872-25-3P 1056872-35-5P 1057641-28-7P
1057641-31-2P 1057641-33-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate and intermediate; preparation of pyrazolopyridine derivs. as phosphodiesterase inhibitors useful in the treatment of diseases)


RN 1056872-25-3 CAPLUS

CN 5-Isoxazoleacetic acid, 3-[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-(methoxycarbonyl)-, methyl ester (CA INDEX NAME)




RN 1056872-35-5 CAPLUS


CN 5(4H)-Isoxazoleethanol, 3-[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-5-(hydroxymethyl)- (CA INDEX NAME)




RN 1057641-28-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1057641-31-2 CAPLUS
CN 5-Isoxazolecarboxylic acid, 5-(bromomethyl)-3-[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-, ethyl ester (CA INDEX NAME)



RN 1057641-33-4 CAPLUS
CN 5-Isoxazolemethanol, 5-(bromomethyl)-3-[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro- (CA INDEX NAME)




IT 1056872-23-1P

RL: PAC (Pharmacological activity); PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prophetic drug candidate and intermediate; preparation of pyrazolopyridine derivs. as phosphodiesterase inhibitors useful in the treatment of diseases)

RN 1056872-23-1 CAPLUS

CN 5,5(4H)-Isoxazolidimethanol, 3-[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)




IT 1057641-85-6P

RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prophetic drug candidate; preparation of pyrazolopyridine derivs. as phosphodiesterase inhibitors useful in the treatment of diseases)

RN 1057641-85-6 CAPLUS

CN 5,5(4H)-Isoxazolidimethanol, 3-[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-, 5,5-dimethanesulfonate (CA INDEX NAME)



REFERENCE COUNT:


6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2008:1123146 CAPLUS
 DOCUMENT NUMBER: 149:355895
 TITLE: Pyrazolo[3,4-b]pyridine derivatives as
 phosphodiesterase inhibitors and their preparation,
 pharmaceutical composition and use in the treatment of
 diseases
 INVENTOR(S): Rudra, Sonali; Gupta, Nidhi; Baregama, Lalit Kumar;
 Agarwal, Ritu; Ramaiah, Mandadapu Raghu; Khairnar,
 Vinayak Vasant Rao; Palle, Venkata P.; Balachandran,
 Sarala; Ray, Abhijit; Dastidar, Sunanda G.;
 Vijaykrishnan, Lalitha
 PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
 SOURCE: PCT Int. Appl., 118pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008111009	A1	20080918	WO 2008-IB50941	20080313
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: IN 2007-DE549 A 20070314
 GI



AB The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4 /PDE type 7 inhibitors. Compsds. disclosed herein have the structure of formula I, which can be useful in the treatment, prevention, inhibition or suppression of CNS diseases, for example, multiple sclerosis; various pathol. conditions such as diseases affecting the immune system, including AIDS, rejection of transplant, auto-immune disorders such as T-cell related diseases, for example, rheumatoid arthritis; inflammatory diseases such as respiratory


inflammation diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS) and other inflammatory diseases including but not limited to psoriasis, shock, atopic dermatitis, eosinophilic granuloma, allergic conjunctivitis, osteoarthritis; gastrointestinal inflammation diseases such as Crohn's disease, colitis, pancreatitis as well as different types of cancers including leukemia; especially in humans. Processes for the preparation of disclosed compds. of formula I, pharmaceutical compns. containing the disclosed compds. and their use as PDE type 4, PDE type 7 and dual PDE type 4 /PDE type 7 inhibitors are provided. Compds. of formula I wherein R1 is H, alkyl, alkenyl, alkynyl, cycloalkyl, (hetero)aryl, etc.; R2 and R3 are independently H, (hetero)aryl, (oxo)cyclohexyl, (oxo)cyclobutyl, tetrahydropyranyl, etc.; R4 and R5 are independently alkyl, CN, (CH2)0-2CONH2 and derivs., (CH2)0-2-CO2H and derivs., and (CH2)0-3OH and derivs.; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compds. were evaluated for their PDE-4 and PDE-7 inhibitory activity. From the assay, it was determined that the tested compds. exhibited IC50 values in the range of 1 nM to 10 μ M against PDE-4 and in the range of 7 nM to 10 μ M against PDE-7.

IT 1056872-25-3P 1056872-31-1P 1056872-33-3P
 1056872-66-2P 1056875-36-5P 1056875-40-1P
 1056875-44-5P 1056875-48-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate and intermediate; preparation of pyrazolopyridine derivs. as phosphodiesterase inhibitors useful in the treatment of diseases)


RN 1056872-25-3 CAPLUS

CN 5-Isloxazoleacetic acid, 3-[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-(methoxycarbonyl)-, methyl ester (CA INDEX NAME)




RN 1056872-31-1 CAPLUS

CN 5,5(4H)-Isloxazolidimethanol, 3-[1-ethyl-4-[(4-hydroxycyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)



RN 1056872-33-3 CAPLUS


CN 5-Isoxazoleacetic acid, 5-carboxy-3-[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro- (CA INDEX NAME)



RN 1056872-66-2 CAPLUS


CN 5-Isoxazoleacetic acid, 5-carboxy-3-[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1056875-36-5 CAPLUS


CN INDEX NAME NOT YET ASSIGNED




RN 1056875-40-1 CAPLUS
 CN 5-Isioxazoleacetic acid, 3-[1-ethyl-4-(4-pyridinylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-(methoxycarbonyl)-, methyl ester (CA INDEX NAME)



RN 1056875-44-5 CAPLUS
 CN 5,5(4H)-Isioxazoledicarboxylic acid, 3-[1-ethyl-4-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)



RN 1056875-48-9 CAPLUS
 CN 5,5(4H)-Isoxazolediacetic acid, 3-[1-ethyl-4-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)



IT 929633-30-7P 929633-31-8P 929633-32-9P
 929633-33-0P 929633-34-1P 929633-35-2P
 929633-37-4P 929633-39-6P 929633-41-0P
 929633-50-1P 929633-56-7P 929633-57-8P
 1056872-23-1P 1056872-27-5P 1056872-29-7P
 1056872-35-5P 1056872-37-7P 1056872-39-9P
 1056872-68-4P 1056872-70-8P 1056872-72-0P
 1056872-74-2P 1056872-76-4P 1056872-78-6P
 1056872-80-0P 1056872-82-2P 1056872-89-9P
 1056872-97-9P 1056873-05-2P 1056873-07-4P
 1056873-09-6P 1056873-13-2P 1056873-19-8P
 1056873-21-2P 1056873-23-4P 1056873-33-6P
 1056873-35-8P 1056873-41-6P 1056873-47-2P
 1056873-49-4P 1056873-55-2P 1056873-57-4P
 1056873-63-2P 1056873-65-4P 1056873-67-6P
 1056873-69-8P 1056873-71-2P 1056873-73-4P
 1056873-75-6P 1056873-79-0P 1056873-81-4P
 1056873-83-6P 1056873-85-8P 1056873-87-0P
 1056873-89-2P 1056873-91-6P 1056873-93-8P
 1056873-95-0P 1056873-97-2P 1056873-99-4P
 1056874-01-1P 1056874-03-3P 1056874-05-5P
 1056874-07-7P 1056874-09-9P 1056874-11-3P
 1056874-13-5P 1056874-15-7P 1056874-17-9P
 1056874-19-1P 1056874-21-5P 1056874-23-7P
 1056874-25-9P 1056874-27-1P 1056874-29-3P
 1056874-31-7P 1056874-33-9P 1056874-35-1P
 1056874-37-3P 1056874-39-5P 1056874-41-9P
 1056874-44-2P 1056874-47-5P 1056874-50-0P
 1056874-53-3P 1056874-56-6P 1056874-59-9P
 1056874-62-4P 1056874-65-7P 1056874-68-0P
 1056874-71-5P 1056874-74-8P 1056874-77-1P
 1056874-80-6P 1056874-83-9P 1056874-86-2P
 1056874-89-5P 1056874-92-0P 1056874-98-6P
 1056875-01-4P 1056875-04-7P 1056875-07-0P
 1056875-10-5P 1056875-13-8P 1056875-16-1P
 1056875-19-4P 1056875-22-9P 1056875-25-2P
 1056875-30-9P 1056875-33-2P 1056875-52-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrazolopyridine derivs. as

phosphodiesterase inhibitors useful in the treatment of diseases)


RN 929633-30-7 CAPLUS

CN 5-Isoxazolecarboxylic acid, 3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-methyl-, methyl ester (CA INDEX NAME)




RN 929633-31-8 CAPLUS

CN 5-Isoxazolemethanol, 3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-methyl- (CA INDEX NAME)




RN 929633-32-9 CAPLUS

CN 5-Isoxazolecarbonitrile, 3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-methyl- (CA INDEX NAME)




RN 929633-33-0 CAPLUS


CN 5-Isoxazoleacetic acid, 3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-(methoxycarbonyl)-, methyl ester (CA INDEX NAME)




RN 929633-34-1 CAPLUS
 CN 5-Isoxazoleacetic acid, 5-carboxy-3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro- (CA INDEX NAME)



RN 929633-35-2 CAPLUS
 CN 5-Isoxazoleacetamide, 5-(aminocarbonyl)-3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro- (CA INDEX NAME)




RN 929633-37-4 CAPLUS
 CN 5(4H)-Isoxazoleethanol, 3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-5-(hydroxymethyl)- (CA INDEX NAME)




RN 929633-39-6 CAPLUS

CN 5-Isioxazolecaboxamide, 3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-methyl- (CA INDEX NAME)




RN 929633-41-0 CAPLUS

CN 5-Isioxazolecaboxylic acid, 3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-methyl- (CA INDEX NAME)




RN 929633-50-1 CAPLUS

CN 5-Isioxazolecaboxylic acid, 3-[4-(cyclopentylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-methyl-, methyl ester (CA INDEX NAME)




RN 929633-56-7 CAPLUS

CN 5-Isoxazoleacetic acid, 3-[4-(cyclopentylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-(methoxycarbonyl)-, methyl ester (CA INDEX NAME)




RN 929633-57-8 CAPLUS

CN 5-Isoxazolemethanol, 3-[4-(cyclopentylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-methyl- (CA INDEX NAME)




RN 1056872-23-1 CAPLUS

CN 5,5(4H)-Isoxazolidimethanol, 3-[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)




RN 1056872-27-5 CAPLUS

5-Isoxazoleacetic acid, 3-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-(methoxycarbonyl)-, methyl ester (CA INDEX NAME)




RN 1056872-29-7 CAPLUS

CN 5,5(4H)-Isoxazoledimethanol, 3-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)




RN 1056872-35-5 CAPLUS


5(4H)-Isoxazoleethanol, 3-[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-5-(hydroxymethyl)- (CA INDEX NAME)



RN 1056872-37-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1056872-39-9 CAPLUS
CN 5-Isoxazoleacetamide, 3-[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-N-methyl-5-[(methylamino)carbonyl]- (CA INDEX NAME)




RN 1056872-68-4 CAPLUS
CN 5-Isoxazoleacetic acid, 5-carboxy-3-[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1056872-70-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1056872-72-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1056872-74-2 CAPLUS
CN 5-Isioxazoleacetamide, 3-[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-N-methyl-5-[(methoxycarbonyl)amino]-, (5S)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 1056872-76-4 CAPLUS


CN 5-Isioxazoleacetamide, 3-[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-N-methyl-5-[(methylamino)carbonyl]-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1056872-78-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1056872-80-0 CAPLUS


CN 5,5(4H)-Isioxazolidimethanol, 3-[1-ethyl-4-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)



RN 1056872-82-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1056872-89-9 CAPLUS
CN 5-Isioxazoleacetamide, 3-[1-ethyl-4-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-N-methyl-5-[(methylamino)carbonyl]- (CA INDEX NAME)




RN 1056872-97-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1056873-05-2 CAPLUS

CN 5,5(4H)-Isoxazolediacetamide, 3-[1-ethyl-4-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N5,N5-dimethyl- (CA INDEX NAME)




RN 1056873-07-4 CAPLUS


CN 5,5(4H)-Isoxazolediacetamide, 3-[1-ethyl-4-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)



RN 1056873-09-6 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1056873-13-2 CAPLUS
 CN 5,5(4H)-Isloxazolidiacetamide, 3-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)




RN 1056873-19-8 CAPLUS

CN 5,5(4H)-Isoxazolidiacetamide, 3-[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)



RN 1056873-21-2 CAPLUS


CN 5,5(4H)-Isoxazolidiacetamide, 3-[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-N5,N5-dimethyl- (CA INDEX NAME)




RN 1056873-23-4 CAPLUS

CN 5,5(4H)-Isoxazolidiacetamide, 3-[1-ethyl-4-[(tetrahydro-2H-pyran-4-


yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N5,N5-dimethyl- (CA INDEX NAME)




RN 1056873-33-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1056873-35-8 CAPLUS
CN 5-Isloxazoleacetamide, 3-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-N-methyl-5-[(methanimino)carbonyl]- (CA INDEX NAME)




RN 1056873-41-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1056873-47-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1056873-49-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1056873-55-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1056873-57-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1056873-63-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1056873-65-4 CAPLUS
CN 5,5(4H)-Isoxazolidinecarboxamide, 3-[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)




RN 1056873-67-6 CAPLUS
 CN 5,5(4H)-Isoxazoledicarboxamide, 3-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)



RN 1056873-69-8 CAPLUS
 CN 5,5(4H)-Isoxazoledicarboxamide, 3-[1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)




RN 1056873-71-2 CAPLUS
 CN 5,5(4H)-Isoxazoledicarboxamide, 3-[1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N,N'-dimethyl- (CA INDEX NAME)




RN 1056873-73-4 CAPLUS

CN 5,5(4H)-Isoxazolidinecarboxamide, N,N'-diethyl-3-[1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)




RN 1056873-75-6 CAPLUS


CN 5,5(4H)-Isoxazolidinecarboxamide, 3-[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-N,N'-dimethyl- (CA INDEX NAME)




RN 1056873-79-0 CAPLUS
 CN 5,5(4H)-Isoxazoledicarboxamide, 3-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N,N'-dimethyl- (CA INDEX NAME)




RN 1056873-81-4 CAPLUS
 CN 5,5(4H)-Isoxazoledicarboxamide, N,N'-diethyl-3-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)




RN 1056873-83-6 CAPLUS
 CN 5,5(4H)-Isoxazoledicarboxamide, 3-[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-N,N'-diethyl- (CA INDEX NAME)




RN 1056873-85-8 CAPLUS
 CN 5,5(4H)-Isoxazolidedicarboxamide, N,N'-dicyclobutyl-3-[1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)




RN 1056873-87-0 CAPLUS
 CN 5,5(4H)-Isoxazolidedicarboxamide, N,N'-dicyclobutyl-3-[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)



RN 1056873-89-2 CAPLUS
 CN 5,5(4H)-Isoxazolidedicarboxamide, N,N'-dicyclobutyl-3-[1-ethyl-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA
 INDEX NAME)




RN 1056873-91-6 CAPLUS
 CN 5,5(4H)-Isoxazolidedicarboxamide, N,N'-dicyclopentyl-3-[1-ethyl-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA
 INDEX NAME)




RN 1056873-93-8 CAPLUS

CN 5,5(4H)-Isoxazolidedicarboxamide, 3-[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-N,N'-dicyclopentyl- (CA INDEX NAME)




RN 1056873-95-0 CAPLUS


CN 5,5(4H)-Isoxazolidedicarboxamide, N,N'-dicyclopentyl-3-[1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)




RN 1056873-97-2 CAPLUS
 CN 5,5(4H)-Isoxazolidedicarboxamide, N,N'-dicyclohexyl-3-[1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)




RN 1056873-99-4 CAPLUS
 CN 5,5(4H)-Isoxazolidedicarboxamide, N,N'-dicyclohexyl-3-[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)




RN 1056874-01-1 CAPLUS
 CN 5,5(4H)-Isoxazolidinecarboxamide, N,N'-dicyclohexyl-3-[1-ethyl-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA
 INDEX NAME)




RN 1056874-03-3 CAPLUS
 CN 5,5(4H)-Isoxazolidinecarboxamide, 3-[1-ethyl-4-[(tetrahydro-2H-pyran-4-
 yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N,N'-bis(1-methylcyclohexyl)-
 (CA INDEX NAME)



RN 1056874-05-5 CAPLUS
 CN 5,5(4H)-Isoxazolidedicarboxamide, 3-[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-N,N'-bis(1-methylcyclohexyl)- (CA INDEX NAME)





RN 1056874-07-7 CAPLUS
 CN 5,5(4H)-Isoxazolidedicarboxamide, 3-[1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N,N'-bis(1-methylcyclohexyl)- (CA INDEX NAME)




RN 1056874-09-9 CAPLUS
 CN 5,5(4H)-Isoxazolidinecarboxamide, 3-[1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N,N'-bis(4-pyridinylmethyl)- (CA INDEX NAME)

PAGE 1-A







RN 1056874-11-3 CAPLUS
 CN 5,5(4H)-Isoxazoledicarboxamide, 3-[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-N,N'-bis(4-pyridinylmethyl)- (CA INDEX NAME)




RN 1056874-13-5 CAPLUS
 CN 5,5(4H)-Isoxazoledicarboxamide, 3-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N,N'-bis(4-pyridinylmethyl)- (CA INDEX NAME)




RN 1056874-15-7 CAPLUS
 CN 5,5(4H)-Isoxazolidedicarboxamide, 3-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N,N'-bis(4-pyridyl)- (CA INDEX NAME)




RN 1056874-17-9 CAPLUS
 CN 5,5(4H)-Isoxazolidedicarboxamide, 3-[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-N,N'-bis(4-fluorophenyl)- (CA INDEX NAME)




RN 1056874-19-1 CAPLUS
 CN 5,5(4H)-Isoxazolidinecarboxamide, 3-[1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N,N'-bis(4-fluorophenyl)- (CA INDEX NAME)




RN 1056874-21-5 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1056874-23-7 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1056874-25-9 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1056874-27-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1056874-29-3 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1056874-31-7 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1056874-33-9 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1056874-35-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1056874-37-3 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1056874-39-5 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1056874-41-9 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1056874-44-2 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1056874-47-5 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1056874-50-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1056874-53-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1056874-56-6 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1056874-59-9 CAPLUS
 CN 5,5(4H)-Isloxazolidedicarboxamide, 3-[1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N,N'-bis[3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (CA INDEX NAME)




RN 1056874-62-4 CAPLUS
 CN 5,5(4H)-Isloxazolidedicarboxamide, 3-[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-N,N'-bis[3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (CA INDEX NAME)




RN 1056874-65-7 CAPLUS
 CN 5,5(4H)-Isoxazoledicarboxamide, 3-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N,N'-bis[3-(phenylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]- (CA INDEX NAME)




RN 1056874-68-0 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 1056874-71-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1056874-74-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1056874-77-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1056874-80-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1056874-83-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1056874-86-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1056874-89-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1056874-92-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1056874-98-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 1056875-01-4 CAPLUS

CN 5-Isloxazoleacetamide, 3-[1-ethyl-4-(3-pyridinylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-N-methyl-5-[(methylamino)carbonyl]- (CA INDEX NAME)




RN 1056875-04-7 CAPLUS

CN 5-Isloxazoleacetamide, 3-[1-ethyl-4-(2-pyrazinylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-N-methyl-5-[(methylamino)carbonyl]- (CA INDEX NAME)




RN 1056875-07-0 CAPLUS

CN 5-Isoxazoleacetamide, 3-[1-ethyl-4-(2-pyrimidinylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-N-methyl-5-[(methylamino)carbonyl]- (CA INDEX NAME)




RN 1056875-10-5 CAPLUS

CN 5-Isoxazoleacetamide, 3-[1-ethyl-4-(1,2,4-triazin-5-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-N-methyl-5-[(methylamino)carbonyl]- (CA INDEX NAME)




RN 1056875-13-8 CAPLUS


CN 5-Isoxazoleacetamide, 3-[1-ethyl-4-(5-pyrimidinylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-N-methyl-5-[(methylamino)carbonyl]- (CA INDEX NAME)




RN 1056875-16-1 CAPLUS
 CN 5-Isioxazoleacetamide, 3-[1-ethyl-4-(4-thiazolylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-N-methyl-5-[(methylamino)carbonyl]- (CA INDEX NAME)




RN 1056875-19-4 CAPLUS
 CN 5-Isioxazoleacetamide, 3-[1-ethyl-4-(4H-1,2,4-triazol-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-N-methyl-5-[(methylamino)carbonyl]- (CA INDEX NAME)




RN 1056875-22-9 CAPLUS
 CN 5-Isoxazoleacetamide, 3-[1-ethyl-4-(4-pyridinylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-N-methyl-5-[(methylamino)carbonyl]- (CA INDEX NAME)



RN 1056875-25-2 CAPLUS
 CN 5-Isoxazoleacetamide, 3-[1-ethyl-4-(2H-tetrazol-5-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-N-methyl-5-[(methylamino)carbonyl]- (CA INDEX NAME)




RN 1056875-30-9 CAPLUS
 CN 5-Isoxazoleacetamide, 3-[1-ethyl-4-(3-furanylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-N-methyl-5-[(methylamino)carbonyl]- (CA INDEX NAME)




RN 1056875-33-2 CAPLUS

CN 5-Isioxazoleacetic acid, 3-[1-ethyl-4-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-(methoxycarbonyl)-, methyl ester (CA INDEX NAME)



RN 1056875-52-5 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




IT 1056876-35-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of pyrazolopyridine derivs. as phosphodiesterase
 inhibitors useful in the treatment of diseases)
 RN 1056876-35-7 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 1056872-66-2
 CMF C20 H25 N5 O5


Absolute stereochemistry.




CM 2

CRN 299-42-3
 CMF C10 H15 N O

Absolute stereochemistry.




IT 1056876-50-6P 1056876-51-7P 1056876-52-8P
 RL: PAC (Pharmacological activity); PRPH (Prophetic); RCT (Reactant); SPN
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
 PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prophetic drug candidate and intermediate; preparation of pyrazolopyridine
 derivs. as phosphodiesterase inhibitors useful in the treatment of
 diseases)
 RN 1056876-50-6 CAPLUS
 CN 5,5(4H)-Isoxazolidimethanol, 3-[1-ethyl-4-[(phenylmethyl)amino]-1H-
 pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)




RN 1056876-51-7 CAPLUS

CN 5-Isoxazoleacetic acid, 3-[1-ethyl-4-[(phenylmethyl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-(methoxycarbonyl)-, methyl ester (CA INDEX NAME)



RN 1056876-52-8 CAPLUS

CN 5-Isoxazoleacetic acid, 3-(4-amino-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-4,5-dihydro-5-(methoxycarbonyl)-, methyl ester (CA INDEX NAME)




IT 1056876-54-0P

RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prophetic intermediate; preparation of pyrazolopyridine derivs. as phosphodiesterase inhibitors useful in the treatment of diseases)

RN 1056876-54-0 CAPLUS

CN 5,5-Isoxazoledicarbonyl dichloride, 3-[1-ethyl-4-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro- (CA INDEX NAME)



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:330210 CAPLUS

DOCUMENT NUMBER: 146:337882

TITLE: Preparation of pyrazolo[3,4-b]pyridines as phosphodiesterase IV inhibitors

INVENTOR(S): Palle, Venakta P.; Balachandran, Sarala; Gupta, Nidhi; Khairnar, Vinayak Vasantrao; Ramaiah, Raghu; Ray, Abhijit; Dastidar, Sunanda Ghose

PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India

SOURCE: PCT Int. Appl., 37pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007031838	A1	20070322	WO 2006-IB2494	20060911
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1934219	A1	20080625	EP 2006-808837	20060911
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
IN 2008DN02840	A	20080725	IN 2008-DN2840	20080404
PRIORITY APPLN. INFO.:			IN 2005-DE2522	A 20050916
			WO 2006-IB2494	W 20060911

OTHER SOURCE(S): MARPAT 146:337882

GI




AB Title compds. [I; P = atoms to form a 6-membered ring containing 1-3 double bonds; M = atoms to form a 5-membered ring containing 1-2 double bonds; X1, X2 = C; X3 = N; R1 = H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, etc.; R2 = H, alkyl, halo, cyano, NO₂, amino, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, etc.; R3 = (substituted) amino, acylamino; R4 = substituted dihydroisoxazolyl], were prepared Thus, a stirred mixture of Me methacrylate and 4-cyclopropylamino-1-ethyl-1H-pyrazolo[3.4-b]pyridine-5-carboxaldehyde oxime (preparation given) in THF was treated with aqueous NaOCl over 5 min followed


by stirring for 4 h to give 51% Me

3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-5-methyl-4,5-dihydroisoxazole-5-carboxylate.


IT 929633-30-7P 929633-31-8P 929633-32-9P
 929633-33-0P 929633-34-1P 929633-35-2P
 929633-37-4P 929633-39-6P 929633-41-0P
 929633-50-1P 929633-56-7P 929633-57-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (claimed compound; preparation of pyrazolopyridines as phosphodiesterase IV
 inhibitors)
 RN 929633-30-7 CAPLUS
 CN 5-Isioxazolecarboxylic acid, 3-[4-(cyclopropylamino)-1-ethyl-1H-
 pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-methyl-, methyl ester (CA
 INDEX NAME)




RN 929633-31-8 CAPLUS
 CN 5-Isioxazolemethanol, 3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-
 b]pyridin-5-yl]-4,5-dihydro-5-methyl- (CA INDEX NAME)




RN 929633-32-9 CAPLUS
 CN 5-Isioxazolecarbonitrile, 3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-
 b]pyridin-5-yl]-4,5-dihydro-5-methyl- (CA INDEX NAME)




RN 929633-33-0 CAPLUS
 CN 5-Isoxazoleacetic acid, 3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-(methoxycarbonyl)-, methyl ester (CA INDEX NAME)




RN 929633-34-1 CAPLUS
 CN 5-Isoxazoleacetic acid, 5-carboxy-3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro- (CA INDEX NAME)



RN 929633-35-2 CAPLUS
 CN 5-Isoxazoleacetamide, 5-(aminocarbonyl)-3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro- (CA INDEX NAME)




RN 929633-37-4 CAPLUS
 CN 5(4H)-Isoxazoleethanol, 3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-5-(hydroxymethyl)- (CA INDEX NAME)




RN 929633-39-6 CAPLUS

CN 5-Isioxazolecarboxamide, 3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-methyl- (CA INDEX NAME)




RN 929633-41-0 CAPLUS

CN 5-Isioxazolecarboxylic acid, 3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-methyl- (CA INDEX NAME)




RN 929633-50-1 CAPLUS

CN 5-Isioxazolecarboxylic acid, 3-[4-(cyclopentylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-methyl-, methyl ester (CA INDEX NAME)




RN 929633-56-7 CAPLUS

CN 5-Isioxazoleacetic acid, 3-[4-(cyclopentylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-(methoxycarbonyl)-, methyl ester (CA INDEX NAME)



RN 929633-57-8 CAPLUS

CN 5-Isioxazolemethanol, 3-[4-(cyclopentylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-5-methyl- (CA INDEX NAME)



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2004:550957 CAPLUS
 DOCUMENT NUMBER: 141:106464
 TITLE: Preparation of pyrazolo[3,4-b]pyridine derivatives for use in pharmaceutical compositions as phosphodiesterase inhibitors
 INVENTOR(S): Allen, David George; Coe, Diane Mary; Cook, Caroline Mary; Cooper, Anthony William James; Dowle, Michael Dennis; Edlin, Christopher David; Hamblin, Julie Nicole; Johnson, Martin Redpath; Jones, Paul Spencer; Lindvall, Mika Kristian; Mitchell, Charlotte Jane; Redgrave, Alison Judith
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 244 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:




PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056823	A1	20040708	WO 2003-EP14867	20031219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2511340	A1	20040708	CA 2003-2511340	20031219
AU 2003293999	A1	20040714	AU 2003-293999	20031219
EP 1581532	A1	20051005	EP 2003-789413	20031219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017645	A	20051206	BR 2003-17645	20031219
CN 1751042	A	20060322	CN 2003-80109835	20031219
JP 2006513258	T	20060420	JP 2005-502565	20031219
AU 2004299277	A1	20050630	AU 2004-299277	20041217
CA 2557004	A1	20050630	CA 2004-2557004	20041217
WO 2005058892	A1	20050630	WO 2004-EP14490	20041217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1737857	A1	20070103	EP 2004-804089	20041217
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
CN 1914205	A	20070214	CN 2004-80041657	20041217
JP 2007514704	T	20070607	JP 2006-544380	20041217
ZA 2005005074	A	20060927	ZA 2005-5074	20050622
IN 2005KN01207	A	20070713	IN 2005-KN1207	20050622

MX 2005PA06923	A	20050818	MX 2005-PA6923	20050623
NO 2005003600	A	20050822	NO 2005-3600	20050722
US 20060252790	A1	20061109	US 2006-540371	20060221
US 20070111995	A1	20070517	US 2006-596561	20060616
IN 2006KN01988	A	20070518	IN 2006-KN1988	20060714
NO 2006003340	A	20060912	NO 2006-3340	20060718
US 20080132536	A1	20080605	US 2008-22372	20080130

PRIORITY APPLN. INFO.:

GB 2002-30045	A	20021223
GB 2002-30165	A	20021224
GB 2003-7998	A	20030407
WO 2003-EP14867	W	20031219
GB 2004-5899	A	20040316
GB 2004-5936	A	20040316
GB 2004-6754	A	20040325
WO 2004-EP14490	W	20041217
US 2006-596561	A1	20060616

OTHER SOURCE(S): MARPAT 141:106464
GI



AB Pyrazolo[3,4-b]pyridine derivs., such as I [R = heterocyclyl; R1 = (CH₂)₂OH, alkyl, fluoroalkyl; R2 = H, Me, fluoroalkyl; R3 = alkyl, (un)substituted-Ph, cycloalkyl, heterocyclyl, etc.; R3a = H, alkyl], were prepared for therapeutic uses as inhibitors of phosphodiesterase, particularly phosphodiesterase IV (PDE4). These pyrazolo[3,4-b]pyridines were claimed for use in the treatment and/or prophylaxis of cognitive impairment and inflammatory and/or allergic diseases, such as chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis. Thus, pyrazolo[3,4-b]pyridine derivative II was prepared via a cyclocondensation reaction of hydrazide III using POCl₃ in MeCN. The prepared pyrazolo[3,4-b]pyridine were assayed for PDE4 inhibitory activity, and systems for delivery of these PDE4 inhibitors were discussed.


IT 720706-29-6P 720706-30-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolo[3,4-b]pyridine derivs. for use in pharmaceutical compns. as phosphodiesterase inhibitors)


RN 720706-29-6 CAPLUS

CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-[[1-(methylamino)cyclohexyl]methyl]- (CA INDEX NAME)



RN 720706-30-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[3-[(3-methoxyphenyl)methyl]-1,2,4-oxadiazol-5-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




IT 720705-76-0P 720705-77-1P 720706-05-8P
720706-06-9P 720706-07-0P 720706-08-1P
720706-10-5P 720706-11-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of pyrazolo[3,4-b]pyridine derivs. for use in pharmaceutical compns. as phosphodiesterase inhibitors)

RN 720705-76-0 CAPLUS


CN 1,2,4-Oxadiazole-3-acetic acid, 5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)




RN 720705-77-1 CAPLUS
 CN 1,2,4-Oxadiazole-3-acetic acid, 5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720706-05-8 CAPLUS
 CN Carbamic acid, [[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 720706-06-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[3-(aminomethyl)-1,2,4-oxadiazol-5-yl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720706-07-0 CAPLUS

CN Butanamide, 4-chloro-N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 720706-08-1 CAPLUS

CN Pentanamide, 5-chloro-N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 720706-10-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 720706-11-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-5-[3-(4-piperidinylmethyl)-1,2,4-oxadiazol-5-yl]-N-(tetrahydro-2H-
 pyran-4-yl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

IT 720703-79-7P 720703-95-7P 720705-31-7P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of pyrazolo[3,4-b]pyridines for use in pharmaceutical compns.
 as phosphodiesterase inhibitors)
 RN 720703-79-7 CAPLUS
 CN 4-Oxazolecarboxylic acid, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-
 1H-pyrazolo[3,4-b]pyridin-5-yl]-, methyl ester (CA INDEX NAME)




RN 720703-95-7 CAPLUS

CN 4-Oxazolecarboxylic acid, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)



RN 720705-31-7 CAPLUS

CN 4-Oxazolecarboxylic acid, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-4,5-dihydro-, methyl ester (CA INDEX NAME)



IT 720703-37-7P 720703-38-8P 720703-39-9P
 720703-40-2P 720703-41-3P 720703-42-4P
 720703-43-5P 720703-44-6P 720703-45-7P
 720703-47-9P 720703-48-0P 720703-49-1P
 720703-50-4P 720703-51-5P 720703-52-6P
 720703-53-7P 720703-54-8P 720703-55-9P
 720703-56-0P 720703-57-1P 720703-58-2P
 720703-59-3P 720703-60-6P 720703-62-8P

720703-63-9P 720703-64-0P 720703-65-1P
 720703-66-2P 720703-67-3P 720703-68-4P
 720703-69-5P 720703-70-8P 720703-71-9P
 720703-72-0P 720703-73-1P 720703-74-2P
 720703-75-3P 720703-76-4P 720703-77-5P
 720703-78-6P 720703-80-0P 720703-81-1P
 720703-82-2P 720703-83-3P 720703-84-4P
 720703-85-5P 720703-86-6P 720703-87-7P
 720703-88-8P 720703-89-9P 720703-90-2P
 720703-91-3P 720703-92-4P 720703-93-5P
 720703-94-6P 720703-96-8P 720703-97-9P
 720703-98-0P 720703-99-1P 720704-00-7P
 720704-01-8P 720704-03-0P 720704-04-1P
 720704-05-2P 720704-06-3P 720704-07-4P
 720704-08-5P 720704-09-6P 720704-10-9P
 720704-11-0P 720704-12-1P 720704-13-2P
 720704-14-3P 720704-15-4P 720704-16-5P
 720704-17-6P 720704-18-7P 720704-19-8P
 720704-20-1P 720704-21-2P 720704-22-3P
 720704-23-4P 720704-24-5P 720704-25-6P
 720704-26-7P 720704-27-8P 720704-28-9P
 720704-29-0P 720704-30-3P 720704-31-4P
 720704-32-5P 720704-33-6P 720704-34-7P
 720704-35-8P 720704-36-9P 720704-37-0P
 720704-38-1P 720704-39-2P 720704-40-5P
 720704-41-6P 720704-42-7P 720704-43-8P
 720704-44-9P 720704-45-0P 720704-46-1P
 720704-47-2P 720704-48-3P 720704-49-4P
 720704-50-7P 720704-51-8P 720704-52-9P
 720704-53-0P 720704-54-1P 720704-56-3P
 720704-57-4P 720704-58-5P 720704-59-6P
 720704-60-9P 720704-61-0P 720704-62-1P
 720704-63-2P 720704-64-3P 720704-65-4P
 720704-66-5P 720704-67-6P 720704-68-7P
 720704-69-8P 720704-70-1P 720704-71-2P
 720704-72-3P 720704-73-4P 720704-74-5P
 720704-75-6P 720704-76-7P 720704-77-8P
 720704-78-9P 720704-79-0P 720704-80-3P
 720704-81-4P 720704-82-5P 720704-83-6P
 720704-84-7P 720704-85-8P 720704-86-9P
 720704-87-0P 720704-88-1P 720704-89-2P
 720704-90-5P 720704-91-6P 720704-92-7P
 720704-93-8P 720704-94-9P 720704-95-0P
 720704-96-1P 720704-97-2P 720704-98-3P
 720704-99-4P 720705-00-0P 720705-01-1P
 720705-02-2P 720705-03-3P 720705-04-4P
 720705-05-5P 720705-06-6P 720705-07-7P
 720705-08-8P 720705-09-9P 720705-10-2P
 720705-11-3P 720705-12-4P 720705-13-5P
 720705-14-6P 720705-15-7P 720705-16-8P
 720705-17-9P 720705-18-0P 720705-19-1P
 720705-20-4P 720705-21-5P 720705-22-6P
 720705-23-7P 720705-24-8P 720705-25-9P
 720705-26-0P 720705-27-1P 720705-28-2P
 720705-29-3P 720708-62-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of pyrazolo[3,4-b]pyridines for use in pharmaceutical compns.
 as phosphodiesterase inhibitors)

RN 720703-37-7 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,

N-cyclopentyl-1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)- (CA INDEX NAME)




RN 720703-38-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
N-cyclopentyl-1-ethyl-5-[5-[(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl]-
(CA INDEX NAME)




RN 720703-39-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
N-cyclopentyl-1-ethyl-5-[5-(1-methylethyl)-1,3,4-oxadiazol-2-yl]- (CA
INDEX NAME)




RN 720703-40-2 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
N-cyclopentyl-1-ethyl-5-(5-methyl-1,3,4-thiadiazol-2-yl)- (CA INDEX NAME)




RN 720703-41-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 N-cyclopentyl-1-ethyl-5-[5-[(methylsulfonyl)methyl]-1,3,4-thiadiazol-2-yl]-
 (CA INDEX NAME)




RN 720703-42-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 N-cyclopentyl-1-ethyl-5-[5-(1-methylethyl)-1,3,4-thiadiazol-2-yl]- (CA
 INDEX NAME)




RN 720703-43-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-N-(4-fluorophenyl)-5-(3-methyl-1,2,4-oxadiazol-5-yl)- (CA INDEX
 NAME)




RN 720703-44-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 N-cyclopentyl-5-(1,3-dimethyl-1H-1,2,4-triazol-5-yl)-1-ethyl- (CA INDEX
 NAME)




RN 720703-45-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-5-[5-(1-methylethyl)-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-
 4-yl)- (CA INDEX NAME)




RN 720703-47-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 N-cyclohexyl-1-ethyl-5-[5-(1-methylethyl)-1,3,4-oxadiazol-2-yl]- (CA
 INDEX NAME)




RN 720703-48-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-5-[5-(1-methylethyl)-1,3,4-oxadiazol-2-yl]-N-(2-methylpropyl)-
 (CA INDEX NAME)




RN 720703-49-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methylpropyl)- (CA INDEX
 NAME)



RN 720703-50-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 N-cyclohexyl-1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)- (CA INDEX NAME)




RN 720703-51-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(tetrahydro-2H-pyran-4-yl)-
 (CA INDEX NAME)




RN 720703-52-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 N-[(1R)-1,2-dimethylpropyl]-1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-
 (CA INDEX NAME)

Absolute stereochemistry.




RN 720703-53-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 N-[(1S)-1,2-dimethylpropyl]-1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-
 (CA INDEX NAME)

Absolute stereochemistry.




RN 720703-54-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1-ethyl-N-(tetrahydro-2H-

pyran-4-yl)- (CA INDEX NAME)




RN 720703-55-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
N-cyclohexyl-5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1-ethyl- (CA
INDEX NAME)




RN 720703-56-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
N-cyclopentyl-5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1-ethyl- (CA
INDEX NAME)




RN 720703-57-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1-ethyl-N-(2-methylpropyl)-
(CA INDEX NAME)




RN 720703-58-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-N-[(1S)-1,2-dimethylpropyl]-
 1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 720703-59-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-N-[(1R)-1,2-dimethylpropyl]-
 1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.




RN 720703-60-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-5-[5-[(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-
 2H-pyran-4-yl)- (CA INDEX NAME)



RN 720703-62-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 N-cyclohexyl-1-ethyl-5-[5-[(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl]-
 (CA INDEX NAME)




RN 720703-63-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-N-(2-methylpropyl)-5-[5-[(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl]-
 (CA INDEX NAME)




RN 720703-64-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 N-[(1S)-1,2-dimethylpropyl]-1-ethyl-5-[5-[(methylsulfonyl)methyl]-1,3,4-oxadiazol-2-yl]-
 (CA INDEX NAME)

Absolute stereochemistry.




RN 720703-65-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 N-[(1R)-1,2-dimethylpropyl]-1-ethyl-5-[5-[(methylsulfonyl)methyl]-1,3,4-
 oxadiazol-2-yl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 720703-66-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)-N-(tetrahydro-2H-pyran-4-yl)-
 (CA INDEX NAME)




RN 720703-67-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-5-[3-(methoxymethyl)-1,2,4-oxadiazol-5-yl]-N-(tetrahydro-2H-pyran-
 4-yl)- (CA INDEX NAME)




RN 720703-68-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 5-[3-[(dimethylamino)methyl]-1,2,4-oxadiazol-5-yl]-1-ethyl-N-(tetrahydro-
 2H-pyran-4-yl)- (CA INDEX NAME)



RN 720703-69-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-5-[3-(4-morpholinylmethyl)-1,2,4-oxadiazol-5-yl]-N-(tetrahydro-2H-
 pyran-4-yl)- (CA INDEX NAME)




RN 720703-70-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 5-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)-1-ethyl-N-(tetrahydro-2H-pyran-4-
 yl)- (CA INDEX NAME)




RN 720703-71-9 CAPLUS

CN Ethanone, 1-[4-[[1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 720703-72-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-(3-methyl-3-oxetanyl)-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720703-73-1 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720703-74-2 CAPLUS
 CN 1,3,4-Oxadiazole-2-carboxamide, 5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-(1-methylethyl)- (CA INDEX NAME)




RN 720703-75-3 CAPLUS
 CN 2-Pyrrolidinone, 4-[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3,4-oxadiazol-2-yl]-1-methyl- (CA INDEX NAME)




RN 720703-76-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-5-[5-(tetrahydro-2H-pyran-4-yl)-1,3,4-oxadiazol-2-yl]- (CA INDEX NAME)




RN 720703-77-5 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
1-ethyl-5-[5-(4-morpholinylmethyl)-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720703-78-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 5-[5-[(1,1-dimethylethoxy)methyl]-1,3,4-oxadiazol-2-yl]-1-ethyl-N-
 (tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720703-80-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 5-(4,5-dihydro-4-methyl-2-oxazolyl)-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-
 (CA INDEX NAME)




RN 720703-81-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,

5-(5-methyl-1,3,4-oxadiazol-2-yl)-1-propyl-N-(tetrahydro-2H-pyran-4-yl)-
(CA INDEX NAME)




RN 720703-82-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
1-ethyl-5-[5-(tetrahydro-2-furanyl)-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-
pyran-4-yl)- (CA INDEX NAME)



RN 720703-83-3 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
5-[5-(dimethylamino)-1,3,4-oxadiazol-2-yl]-1-ethyl-N-(tetrahydro-2H-pyran-
4-yl)- (CA INDEX NAME)



RN 720703-84-4 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,

1-ethyl-5-(3-methyl-1H-1,2,4-triazol-5-yl)-N-(tetrahydro-2H-pyran-4-yl)-
(CA INDEX NAME)




RN 720703-85-5 CAPLUS

CN Ethanone, 1-[4-[[1-ethyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 720703-86-6 CAPLUS

CN Ethanone, 1-[4-[[1-ethyl-5-[3-(4-morpholinylmethyl)-1,2,4-oxadiazol-5-yl]-1H-pyrazolo[3,4-b]pyridin-4-yl]amino]-1-piperidinyl]- (CA INDEX NAME)




RN 720703-87-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,

5-[(4R)-4,5-dihydro-4-phenyl-2-oxazolyl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 720703-88-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
5-[(4S)-4,5-dihydro-4-phenyl-2-oxazolyl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 720703-89-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
5-[(4S)-4,5-dihydro-4-(phenylmethyl)-2-oxazolyl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 720703-90-2 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
5-[(4R)-4,5-dihydro-4-(phenylmethyl)-2-oxazolyl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 720703-91-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
5-[(4S,5R)-4,5-dihydro-5-methyl-4-phenyl-2-oxazolyl]-1-ethyl-N-(tetrahydro-
2H-pyran-4-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 720703-92-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
5-[(5R)-4,5-dihydro-5-phenyl-2-oxazolyl]-1-ethyl-N-(tetrahydro-2H-pyran-4-
yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 720703-93-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
5-[(5S)-4,5-dihydro-5-phenyl-2-oxazolyl]-1-ethyl-N-(tetrahydro-2H-pyran-4-
yl)- (CA INDEX NAME)


Absolute stereochemistry.




RN 720703-94-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 5-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720703-96-8 CAPLUS
 CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-(1-methylethyl)- (CA INDEX NAME)



RN 720703-97-9 CAPLUS
 CN Methanone, [2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-4-oxazolyl]-4-morpholinyl- (CA INDEX NAME)




RN 720703-98-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-N-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(tetrahydro-2H-pyran-
 4-yl)- (CA INDEX NAME)




RN 720703-99-1 CAPLUS
 CN Cyclohexanol, 4-[[1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-
 pyrazolo[3,4-b]pyridin-4-yl]amino]-, trans- (CA INDEX NAME)

Relative stereochemistry.




RN 720704-00-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(tetrahydro-2H-pyran-3-yl)-
 (CA INDEX NAME)




RN 720704-01-8 CAPLUS

CN Cyclohexanone, 4-[[1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]amino]- (CA INDEX NAME)




RN 720704-03-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)-N-propyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-04-1 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 5-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1-ethyl-6-methyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-05-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-6-methyl-N-(tetrahydro-2H-pyran-4-yl)-5-[5-(tert-butyl)-1,3,4-oxadiazol-2-yl]- (CA INDEX NAME)



RN 720704-06-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 5-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-07-4 CAPLUS
 CN 2-Pyrrolidinone, 5-[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3,4-oxadiazol-2-yl]- (CA INDEX NAME)




RN 720704-08-5 CAPLUS

CN Acetamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3,4-oxadiazol-2-yl]methyl]- (CA INDEX NAME)



RN 720704-09-6 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-(1-methyl-2-piperidinyl)-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720704-10-9 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-[(4-methyl-1,2,5-oxadiazol-3-yl)methyl]-1,3,4-oxadiazol-2-yl]-

N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720704-11-0 CAPLUS


CN Cyclopentanone, 3-[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3,4-oxadiazol-2-yl]- (CA INDEX NAME)




RN 720704-12-1 CAPLUS

CN 2-Thiazolidinone, 4-[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3,4-oxadiazol-2-yl]-, (4S)- (CA INDEX NAME)


Absolute stereochemistry.




RN 720704-13-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 5-[5-(2,2-dimethylcyclopropyl)-1,3,4-oxadiazol-2-yl]-1-ethyl-N-(tetrahydro-
 2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-14-3 CAPLUS
 CN Acetamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
 pyrazolo[3,4-b]pyridin-5-yl]-1,3,4-oxadiazol-2-yl]methyl]-N-methyl- (CA
 INDEX NAME)




RN 720704-15-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-5-[5-[(1-ethyl-4-[(tetrahydro-2H-pyran-4-
 yl)methyl]-1,3,4-oxadiazol-2-yl]-1,3,4-oxadiazol-2-yl]- (CA INDEX NAME)



RN 720704-16-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-5-[5-(1-methylcyclobutyl)-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-
 pyran-4-yl)- (CA INDEX NAME)




RN 720704-17-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-5-[5-(3-methyl-5-isoxazolyl)-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-
 2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-18-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
1-ethyl-5-[5-(1-methyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2-yl]-N-
(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-19-8 CAPLUS

CN Ethanone, 1-[4-[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
pyrazolo[3,4-b]pyridin-5-yl]-1,3,4-oxadiazol-2-yl]-1-piperidinyl]- (CA
INDEX NAME)




RN 720704-20-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
1-ethyl-5-[3-[(4-methyl-1-piperazinyl)methyl]-1,2,4-oxadiazol-5-yl]-N-
(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720704-21-2 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
1-ethyl-5-[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]-N-(tetrahydro-2H-pyran-
4-yl)- (CA INDEX NAME)



RN 720704-22-3 CAPLUS


CN Ethanone, 2-[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-

pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]-1-(1-pyrrolidinyl)-
(CA INDEX NAME)




RN 720704-23-4 CAPLUS

CN 1,2,4-Oxadiazole-3-acetamide, 5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-phenyl- (CA INDEX NAME)




RN 720704-24-5 CAPLUS

CN 1,2,4-Oxadiazole-3-acetamide, 5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-(1-phenylethyl)- (CA INDEX NAME)




RN 720704-25-6 CAPLUS

CN Ethanone, 2-[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]-1-(1-piperidinyl)- (CA INDEX NAME)




RN 720704-26-7 CAPLUS

CN 1,2,4-Oxadiazole-3-acetamide, 5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-(phenylmethyl)- (CA INDEX NAME)




RN 720704-27-8 CAPLUS

CN 1,2,4-Oxadiazole-3-acetamide, 5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 720704-28-9 CAPLUS


CN 1,2,4-Oxadiazole-3-acetamide, N-ethyl-5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)




RN 720704-29-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-5-[3-[1-(4-morpholinyl)ethyl]-1,2,4-oxadiazol-5-yl]-N-(tetrahydro-
 2H-pyran-4-yl)- (CA INDEX NAME)



RN 720704-30-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 5-[3-(cyclohexylmethyl)-1,2,4-oxadiazol-5-yl]-1-ethyl-N-(tetrahydro-2H-
 pyran-4-yl)- (CA INDEX NAME)




RN 720704-31-4 CAPLUS
 CN Ethanone, 2-[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
 pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]-1-(4-morpholinyl)- (CA
 INDEX NAME)




RN 720704-32-5 CAPLUS

CN Ethanone, 2-[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]-1-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 720704-33-6 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-5-[5-(1H-1,2,3-triazol-1-ylmethyl)-1,3,4-oxadiazol-2-yl]- (CA INDEX NAME)



RN 720704-34-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,


5-[5-[(2,4-dimethyl-5-thiazolyl)methyl]-1,3,4-oxadiazol-2-yl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720704-35-8 CAPLUS
 CN Formic acid, compd. with 5-[5-[(2,4-dimethyl-5-thiazolyl)methyl]-1,3,4-oxadiazol-2-yl]-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (1:1) (CA INDEX NAME)


CM 1

CRN 720704-34-7
 CMF C21 H25 N7 O2 S




CM 2

CRN 64-18-6
 CMF C H2 O2




RN 720704-36-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-5-[5-(2-furanylmethyl)-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-
 pyran-4-yl)- (CA INDEX NAME)



RN 720704-37-0 CAPLUS
 CN Formic acid, compd. with 1-ethyl-5-[5-(2-furanylmethyl)-1,3,4-oxadiazol-2-
 yl]-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (1:1)
 (CA INDEX NAME)


CM 1

CRN 720704-36-9
 CMF C20 H22 N6 O3




CM 2

CRN 64-18-6
 CMF C H2 O2




RN 720704-38-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-5-[5-(3-isoxazolylmethyl)-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-
 pyran-4-yl)- (CA INDEX NAME)



RN 720704-39-2 CAPLUS
 CN Formic acid, compd. with 1-ethyl-5-[5-(3-isoxazolylmethyl)-1,3,4-oxadiazol-
 2-yl]-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (1:1)
 (CA INDEX NAME)


CM 1

CRN 720704-38-1
 CMF C19 H21 N7 O3




CM 2

CRN 64-18-6
CMF C H2 O2




RN 720704-40-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
1-ethyl-5-[5-[(4-methoxyphenyl)methyl]-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-
2H-pyran-4-yl)- (CA INDEX NAME)



RN 720704-41-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
1-ethyl-5-[5-[(4-methoxyphenyl)methyl]-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-
2H-pyran-4-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 720704-40-5
CMF C23 H26 N6 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 720704-42-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-5-[5-(1H-tetrazol-1-ylmethyl)-1,3,4-
oxadiazol-2-yl]- (CA INDEX NAME)




RN 720704-43-8 CAPLUS

CN Formic acid, compd. with 1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-5-[5-(1H-tetrazol-1-ylmethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazolo[3,4-b]pyridin-4-amine (1:1) (CA INDEX NAME)

CM 1

CRN 720704-42-7

CMF C17 H20 N10 O2



CM 2


CRN 64-18-6

CMF C H2 O2


$\text{O}=\text{CH}-\text{OH}$

RN 720704-44-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
1-ethyl-5-[5-(5-isothiazolylmethyl)-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-45-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-5-[5-[(3-methyl-5-isoxazolyl)methyl]-1,3,4-oxadiazol-2-yl]-N-
 (tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720704-46-1 CAPLUS
 CN Formic acid, compd. with 1-ethyl-5-[5-[(3-methyl-5-isoxazolyl)methyl]-
 1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-
 b]pyridin-4-amine (1:1) (CA INDEX NAME)

CM 1


CRN 720704-45-0
 CMF C20 H23 N7 O3



CM 2


CRN 64-18-6

CMF C H2 O2



RN 720704-47-2 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
5-[5-[[4-(dimethylamino)phenyl]methyl]-1,3,4-oxadiazol-2-yl]-1-ethyl-N-
(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720704-48-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
1-ethyl-5-[5-[(2-methyl-4-thiazolyl)methyl]-1,3,4-oxadiazol-2-yl]-N-

(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-49-4 CAPLUS

CN Formic acid, compd. with 1-ethyl-5-[5-[(2-methyl-4-thiazolyl)methyl]-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (1:1) (CA INDEX NAME)

CM 1

CRN 720704-48-3


CMF C20 H23 N7 O2 S



CM 2


CRN 64-18-6

CMF C H2 O2



RN 720704-50-7 CAPLUS

CN Cyclopentaneacetamide, 1-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3,4-oxadiazol-2-yl]methyl]-N-methyl-
(CA INDEX NAME)




RN 720704-51-8 CAPLUS

CN Cyclopentaneacetamide, 1-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3,4-oxadiazol-2-yl]methyl]-N-methyl-,
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 720704-50-7


CMF C24 H33 N7 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 720704-52-9 CAPLUS

CN Cyclopropanecarboxamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3,4-oxadiazol-2-yl]methyl]-(CA INDEX NAME)



RN 720704-53-0 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-[(5-methyl-3-isoxazolyl)methyl]-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720704-54-1 CAPLUS
CN Formic acid, compd. with 1-ethyl-5-[5-[(5-methyl-3-isoxazolyl)methyl]-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (1:1) (CA INDEX NAME)


CM 1

CRN 720704-53-0
CMF C20 H23 N7 O3




CM 2

CRN 64-18-6
CMF C H2 O2



RN 720704-56-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[5-[2-(4-methyl-5-thiazolyl)ethyl]-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-57-4 CAPLUS

CN Formic acid, compd. with 1-ethyl-5-[5-[2-(4-methyl-5-thiazolyl)ethyl]-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (1:1) (CA INDEX NAME)

CM 1

CRN 720704-56-3


CMF C21 H25 N7 O2 S




CM 2

CRN 64-18-6

CMF C H2 O2




RN 720704-58-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 5-[5-[(3,5-dimethyl-4-isoxazolyl)methyl]-1,3,4-oxadiazol-2-yl]-1-ethyl-N-
 (tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720704-59-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 5-[5-[(3,5-dimethyl-4-isoxazolyl)methyl]-1,3,4-oxadiazol-2-yl]-1-ethyl-N-
 (tetrahydro-2H-pyran-4-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)




CM 1

CRN 720704-58-5
 CMF C21 H25 N7 O3




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




CRN 720704-61-0
CMF C23 H31 N7 O3




CM 2


CRN 76-05-1
CMF C2 H F3 O2




RN 720704-63-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
1-ethyl-5-[5-[(4-methylphenyl)methyl]-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-
2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-64-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-5-[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-
 4-yl)- (CA INDEX NAME)




RN 720704-65-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 5-[5-(3,4-dimethylphenyl)-1,3,4-oxadiazol-2-yl]-1-ethyl-N-(tetrahydro-2H-
 pyran-4-yl)- (CA INDEX NAME)



RN 720704-66-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 5-[5-(2,4-dimethylphenyl)-1,3,4-oxadiazol-2-yl]-1-ethyl-N-(tetrahydro-2H-
 pyran-4-yl)- (CA INDEX NAME)




RN 720704-67-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 5-[5-[(4-bromophenyl)methyl]-1,3,4-oxadiazol-2-yl]-1-ethyl-N-(tetrahydro-
 2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-68-7 CAPLUS

CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-(phenylmethyl)- (CA INDEX NAME)



RN 720704-69-8 CAPLUS


CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)



RN 720704-70-1 CAPLUS


CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-

pyrazolo[3,4-b]pyridin-5-yl]-N-[(2-methylphenyl)methyl]- (CA INDEX NAME)




RN 720704-71-2 CAPLUS

CN 4-Oxazolecaboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-[(4-methylphenyl)methyl]- (CA INDEX NAME)




RN 720704-72-3 CAPLUS

CN 4-Oxazolecaboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-[(3-methylphenyl)methyl]- (CA INDEX NAME)




RN 720704-73-4 CAPLUS


CN 4-Oxazolecaboxamide, N-[(4-chlorophenyl)methyl]-2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)




RN 720704-74-5 CAPLUS
 CN 4-Oxazolecarboxamide, N-[(2,3-dimethylphenyl)methyl]-2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)



RN 720704-75-6 CAPLUS
 CN 4-Oxazolecarboxamide, N-[(3,5-dimethylphenyl)methyl]-2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)




RN 720704-76-7 CAPLUS
 CN 4-Oxazolecarboxamide, N-[(3,4-dimethylphenyl)methyl]-2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)



RN 720704-77-8 CAPLUS


CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-(1-phenylethyl)- (CA INDEX NAME)



RN 720704-78-9 CAPLUS

CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-[(1R)-1-(4-methoxyphenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 720704-79-0 CAPLUS

CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 720704-80-3 CAPLUS
 CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-(4-methylphenyl)- (CA INDEX NAME)



RN 720704-81-4 CAPLUS
 CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]- (CA INDEX NAME)




RN 720704-82-5 CAPLUS
 CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-[[4-(methylsulfonyl)phenyl]methyl]- (CA INDEX NAME)




RN 720704-83-6 CAPLUS

CN 4-Oxazolecarboxamide, N-(1-acetyl-4-piperidiny)-2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)




RN 720704-84-7 CAPLUS

CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-85-8 CAPLUS

CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)




RN 720704-86-9 CAPLUS

CN 4-Oxazolecarboxamide, 2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)




RN 720704-87-0 CAPLUS

CN 4-Oxazolecarboxamide, N-[1-(aminomethyl)cyclohexyl]-2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-methyl- (CA INDEX NAME)




RN 720704-88-1 CAPLUS


CN 4-Oxazolecarboxamide, N-(2,6-dimethylphenyl)-2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)




RN 720704-89-2 CAPLUS
 CN 4-Oxazolecarboxamide, N-[[4-(aminocarbonyl)phenyl]methyl]-2-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]- (CA INDEX NAME)



RN 720704-90-5 CAPLUS
 CN 1,2,4-Oxadiazole-3-acetamide, 5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-91-6 CAPLUS
 CN Ethanone, 1-(2,6-dimethyl-4-morpholinyl)-2-[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 720704-92-7 CAPLUS

CN Ethanone, 2-[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]-1-(4-methyl-1-piperidinyl)- (CA INDEX NAME)




RN 720704-93-8 CAPLUS

CN 1,2,4-Oxadiazole-3-acetamide, 5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-(2-methoxy-1-methylethyl)- (CA INDEX NAME)




RN 720704-94-9 CAPLUS

CN Ethanone, 1-(3,5-dimethyl-1-piperidinyl)-2-[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 720704-95-0 CAPLUS

CN Ethanone, 2-[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]-1-(3-methyl-1-piperidinyl)- (CA INDEX NAME)




RN 720704-96-1 CAPLUS

CN 1,2,4-Oxadiazole-3-acetamide, 5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-N-3-pyridinyl- (CA INDEX NAME)




RN 720704-97-2 CAPLUS

CN 2-Piperidinone, 6-[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,3,4-oxadiazol-2-yl]- (CA INDEX NAME)




RN 720704-98-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
1-ethyl-5-[5-[(3-methyl-1H-1,2,4-triazol-5-yl)methyl]-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720704-99-4 CAPLUS


CN Acetamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 720705-00-0 CAPLUS
 CN Benzamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)



RN 720705-01-1 CAPLUS
 CN Benzeneacetamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 720705-02-2 CAPLUS
 CN Propanamide, N-[[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]-2-methyl]- (CA INDEX NAME)




RN 720705-03-3 CAPLUS

CN Butanamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]-3-methyl- (CA INDEX NAME)




RN 720705-04-4 CAPLUS

CN Cyclohexanecarboxamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 720705-05-5 CAPLUS

CN 2-Furancarboxamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 720705-06-6 CAPLUS

CN Methanesulfonamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 720705-07-7 CAPLUS

CN Benzenesulfonamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 720705-08-8 CAPLUS

CN Benzenemethanesulfonamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 720705-09-9 CAPLUS

CN 2-Propanesulfonamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 720705-10-2 CAPLUS

CN 1-Propanesulfonamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 720705-11-3 CAPLUS

CN Cyclopropanesulfonamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 720705-12-4 CAPLUS

CN 2-Thiophenesulfonamide, N-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 720705-13-5 CAPLUS

CN 2-Pyrrolidinone, 1-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 720705-14-6 CAPLUS

CN 2-Piperidinone, 1-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]- (CA INDEX NAME)




RN 720705-15-7 CAPLUS

CN Ethanone, 1-[4-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]-1-piperidinyl]-(CA INDEX NAME)




RN 720705-16-8 CAPLUS

CN 1-Butanone, 1-[4-[[5-[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]-1,2,4-oxadiazol-3-yl]methyl]-1-piperidinyl]-3-methyl-(CA INDEX NAME)




RN 720705-17-9 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridin-4-amine, 1-ethyl-5-[3-[[1-(methylsulfonyl)-4-piperidinyl]methyl]-1,2,4-oxadiazol-5-yl]-N-(tetrahydro-2H-pyran-4-yl)-(CA INDEX NAME)




RN 720705-18-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-5-[3-[1-(phenylsulfonyl)cyclopropyl]-1,2,4-oxadiazol-5-yl]-N-
 (tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720705-19-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-5-[3-(phenylmethyl)-1,2,4-oxadiazol-5-yl]-N-(tetrahydro-2H-pyran-4-
 yl)- (CA INDEX NAME)




RN 720705-20-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-5-[3-(1-phenylethyl)-1,2,4-oxadiazol-5-yl]-N-(tetrahydro-2H-pyran-4-
 yl)- (CA INDEX NAME)




RN 720705-21-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-5-[3-[(4-methoxyphenyl)methyl]-1,2,4-oxadiazol-5-yl]-N-(tetrahydro-
 2H-pyran-4-yl)- (CA INDEX NAME)




RN 720705-22-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 5-[3-[[4-(dimethylamino)phenyl]methyl]-1,2,4-oxadiazol-5-yl]-1-ethyl-N-
 (tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720705-23-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 5-[3-[[3-(dimethylamino)phenyl]methyl]-1,2,4-oxadiazol-5-yl]-1-ethyl-N-
 (tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720705-24-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-5-[3-(phenoxymethyl)-1,2,4-oxadiazol-5-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720705-25-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-5-[3-[(5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyridin-3-yl)methyl]-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 720705-26-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-5-[3-[(4-phenyl-1-piperazinyl)methyl]-1,2,4-oxadiazol-5-yl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 720705-27-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-5-((5-ethyl-1,2,4-oxadiazol-3-yl)-N-(tetrahydro-2H-pyran-4-yl)-
 (CA INDEX NAME)




RN 720705-28-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 5-[5-[[4-(dimethylamino)phenyl]methyl]-1,2,4-oxadiazol-3-yl]-1-ethyl-N-
 (tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720705-29-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-5-[[5-[(4-methoxyphenyl)methyl]-1,2,4-oxadiazol-3-yl]-N-(tetrahydro-
 2H-pyran-4-yl)- (CA INDEX NAME)



RN 720708-62-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridin-4-amine,
 1-ethyl-5-[5-(tetrahydro-3-furanyl)-1,3,4-oxadiazol-2-yl]-N-(tetrahydro-2H-
 pyran-4-yl)- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

22.76

201.33

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.20

-3.20

Connection closed by remote host